Oxytrex®: an oxycodone and ultra-low-dose naltrexone formulation
- 9 August 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 16 (8) , 1277-1283
Abstract
Oxytrex® (Pain Therapeutics, Inc.) is an oral opioid that combines a therapeutic amount of oxycodone with an ultra-low dose of the antagonist naltrexone. Animal data indicate that this combination minimizes the development of physical dependence and analgesic tolerance while prolonging analgesia. Oxytrex is in late-stage clinical development by Pain Therapeutics for the treatment of moderate-to-severe chronic pain. To evaluate the safety and efficacy of the oxycodone/naltrexone combination, three clinical studies have been conducted, one in healthy volunteers and the other two in patients with chronic pain. The putative mechanism of ultra-low-dose naltrexone is to prevent an alteration in G-protein coupling by opioid receptors that is associated with opioid tolerance and dependence. Opioid agonists are initially inhibitory but become excitatory through constant opioid receptor activity. The agonist/antagonist combination of Oxytrex may reduce the conversion from an inhibitory to an excitatory receptor, th...Keywords
This publication has 11 references indexed in Scilit:
- Oxytrex Minimizes Physical Dependence While Providing Effective Analgesia: A Randomized Controlled Trial in Low Back PainThe Journal of Pain, 2006
- Gβγ that interacts with adenylyl cyclase in opioid tolerance originates from a Gs proteinJournal of Neurobiology, 2006
- Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in ratsPharmacology Biochemistry and Behavior, 2005
- Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in ratsPsychopharmacology, 2005
- Adding Ultralow-Dose Naltrexone to Oxycodone Enhances and Prolongs Analgesia: A Randomized, Controlled Trial of OxytrexThe Journal of Pain, 2005
- Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor–G protein coupling and Gβγ signalingNeuroscience, 2005
- Low dose naltrexone therapy in multiple sclerosisMedical Hypotheses, 2005
- Ultra-Low Dose Oral Naltrexone Decreases Side Effects and Potentiates the Effect of MethadoneJournal of Pain and Symptom Management, 2003
- Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liabilityPain, 2000
- Opioids can evoke direct receptor-mediated excitatory effects on sensory neuronsTrends in Pharmacological Sciences, 1990